K8凯发

新闻中心

关爱生命与健康     为人类健康做出贡献

媒体报道

JRF101亮相SNO 2026国际年会:获国际神经肿瘤专家关注并有助于潜在临床合作

发布时间:2026-11-16 10:21:38       阅读:


关于 SNO 会议

神经肿瘤学会(Society for Neuro-Oncology,SNO)是全球神经肿瘤领域规模最大、最具影响力的专业学术组织,其年会是该领域最重要的国际学术盛会。每年吸引来自40多个国家,超过3000名神经肿瘤研究者与临床科学家参会,集中发布中枢神经系统肿瘤领域的前沿研究数据与创新疗法进展。2026年第31届年会暨教育日于11月12–15日在美国费城宾夕法尼亚会议中心举行,会议主题为“Crossing the Translational Divide: From Neurons to Novel Therapies”。



近期,K8凯发医药团队赴美国费城参加2026年神经肿瘤学会(Society for Neuro-Oncology,SNO)第31届年会。在此次年会上,公司自主研发的JRF101(脂质体注射制剂)用于治疗复发性胶质母细胞瘤(Recurrent Glioblastoma,GBM)的最新临床研究进展正式亮相。展示期间,JRF101吸引了来自美国及国际神经肿瘤领域的临床专家、医生和研究人员广泛关注,多项潜在临床合作意向正在持续推进。

本次展示的学术海报题为《Liposomal Honokiol (JRF101): A Major Advance in Recurrent GBM》(海报编号:TIP-24),重点介绍了JRF101在贝伐珠单抗预治疗的复发或进展性胶质母细胞瘤患者中的Ⅱ期临床研究,以及Ⅰ期研究的长期随访数据。

微信图片_20261116093227.jpg


         临床研究数据展现持续信号

根据截至2026年10月10日更新的54例患者探索性分析数据,JRF101组的中位总体生存期(mOS)为8.15个月,对照组为3.48个月,风险比(HR)为0.440,名义P值为0.0176。

上述阶段性研究结果显示,JRF101在贝伐珠单抗预治疗的复发性胶质母细胞瘤患者中展现出持续的临床信号,为后续临床研究的深入召开给予了重要依据。

海报同时系统呈现了临床研究设计、疗效分析、安全性数据、脂质体制剂特点及后续临床开发规划。

微信图片_20261116093233.jpg


         国际专家高度关注,临床合作取得持续进展

海报展示期间,JRF101的临床研究数据及脂质体药物研发方向吸引了众多神经肿瘤领域专家驻足研讨。现场讨论围绕JRF101的临床应用潜力、脂质体药物递送技术、脑部药物递送,以及复发性胶质母细胞瘤未被满足的临床治疗需求等多个方面展开。

值得关注的是会议期间及会后,公司已陆续收到多位美国神经肿瘤领域临床医生和专家的邮件。对方表达了对JRF101研究成果的浓厚兴趣,并主动提出进一步分析临床数据、召开学术研讨及探讨临床研究合作的意愿。

其中一位临床专家提到,此前已有该药物活性成分非脂质体制剂的临床使用经验,因此特别关注JRF101脂质体制剂的特点及相关临床研究成果。

这些持续反馈体现了国际临床学术界对JRF101肿瘤治疗研究方向的高度关注,也为公司进一步拓展美国临床研究合作网络创造了新的契机。

微信图片_20261116093210.jpg

         
         持续推进国际临床研究与合作

公司将以此次SNO 2026年会为新的起点,继续推进JRF101的临床研究及国际化开发进程,持续寻求与美国及全球神经肿瘤领域的临床专家、医疗组织和科研团队建立深度合作。

未来,公司将持续有助于JRF101的临床研究,探索其在胶质母细胞瘤及其他实体瘤领域的应用潜力,并顺利获得国际科研合作加快创新研究成果向临床应用的转化。

此次SNO 2026的学术展示,既是JRF101临床研究阶段性成果的一次重要国际研讨,也是公司拓展美国临床研究合作、提升国际学术影响力的关键一步。公司期待与更多国际临床专家及科研组织召开深入合作,共同探索创新肿瘤治疗方案,惠及全球患者。


 

JRF101 Presented at SNO 2026 Annual Meeting: Drawing International Attention and Advancing Potential Clinical Collaborations

About SNO

The Society for Neuro-Oncology (SNO) is the largest and most influential professional organization in neuro-oncology. Its Annual Meeting is the premier international forum in the field, attracting more than 3,000 researchers and clinician-scientists from over 40 countries each year and presenting the latest data and therapeutic advances in central nervous system tumors. The 31st Annual Meeting & Education Day took place on November 12–15, 2026, at the Pennsylvania Convention Center in Philadelphia, under the theme “Crossing the Translational Divide: From Neurons to Novel Therapies.”


Recently, a team from Kinrevi traveled to Philadelphia, USA, to attend the 31st Annual Meeting of the Society for Neuro-Oncology (SNO). At the conference, the Company presented the latest clinical research progress of JRF101, its proprietary liposomal injectable formulation, for the treatment of recurrent glioblastoma (GBM). The presentation drew considerable attention from neuro-oncology clinicians, physicians, and researchers from the United States and around the world, with multiple potential clinical collaboration opportunities now under active discussion.

The poster, entitled "Liposomal Honokiol (JRF101): A Major Advance in Recurrent GBM" (Poster No. TIP-24), highlighted the Phase II clinical study of JRF101 in patients with bevacizumab-pretreated recurrent or progressive GBM, together with long-term follow-up data from the Phase I study.

Clinical Data Demonstrate Encouraging Signals

Based on the exploratory analysis of 54 patients, with data updated through October 10, 2026, the median overall survival (mOS) was 8.15 months in the JRF101 group, compared with 3.48 months in the control group. The reported hazard ratio (HR) was 0.440, with a nominal P value of 0.0176.

These interim findings demonstrate an encouraging clinical signal for JRF101 in bevacizumab-pretreated recurrent GBM and provide a strong rationale for further clinical investigation.

The poster also presented the clinical study design, efficacy analyses, safety profile, liposomal formulation characteristics, and the Company's clinical development strategy going forward.

Strong International Interest and Emerging Collaboration Opportunities

During the poster session, JRF101's clinical data and liposomal drug development program attracted significant interest from neuro-oncology specialists and clinical researchers. Discussions focused on JRF101's therapeutic potential, liposomal drug delivery technology, drug delivery to the brain, and the unmet medical needs of patients with recurrent GBM.

Notably, during and following the conference, the Company received email inquiries from multiple U.S.-based neuro-oncology clinicians and experts expressing strong interest in JRF101 and its clinical research findings.

These clinicians expressed their willingness to learn more about the clinical data, engage in scientific discussions, and explore potential clinical research collaborations with the Company.

One clinical expert also noted prior clinical experience with non-liposomal formulations of the same active ingredient, and expressed particular interest in learning more about JRF101's liposomal formulation and its ongoing clinical development.

These interactions reflect growing international academic interest in JRF101 as a tumor therapeutic approach, and create new opportunities for the Company to expand its clinical research network and collaborations in the United States.

Advancing International Clinical Development and Research Partnerships

Building on the positive engagement at SNO 2026, the Company will continue to advance the clinical research and international development of JRF101, and actively pursue collaborations with neuro-oncology clinicians, medical institutions, and research organizations in the United States and globally.

The Company remains committed to advancing the clinical investigation of JRF101 and exploring its potential applications in glioblastoma and other solid tumors. Through international scientific and clinical partnerships, the Company aims to accelerate the translation of innovative research into clinical applications that benefit patients worldwide.

The presentation at SNO 2026 marks an important milestone in the international clinical development of JRF101, further strengthening the Company's efforts to establish global scientific partnerships and expand clinical research collaborations in the United States.